4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2022 Conference
4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)